The importance of detecting cytomegalovirus infections in studies evaluating new therapies for severe sepsis

Critical Care Medicine

Volumn 38, Issue 10 SUPPL., 2010, Pages

  Kalil, Andre C ^a   Sun, Junfeng ^b   Florescu, Diana F ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Cytomegalovirus; Immunocom promised; Sepsis; Survival outcome; Trial design

Indexed keywords

ACTIVATED PROTEIN C;

CONFERENCE PAPER; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; HUMAN; MEDICAL RESEARCH; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RELIABILITY; SEPSIS; SURVIVAL;

EID: 78650405516     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e3181f20319     Document Type: Conference Paper

References (14)

1. Stanberry LR, Rosenthal SL, Mills L, et al: Longitudinal risk of herpes simplex virus (HSV) type 1, HSV type 2, and cytomegalo-virus infections among young adolescent girls. Clin Infect Dis 2004;39:1433-1438
2. Rafailidis PI, Mourtzoukou EG, Varbobitis IC, et al: Severe cytomegalovirus infection in apparently immunocompetent patients: A systematic review. Virol J 2008;5:47
3. Kalil AC, Levitsky J, Lyden E, et al: Meta-analysis: The efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2005;143:870-880
4. Boeckh M, Nichols WG, Papanicolaou G, et al: Cytomegalovirus in hematopoietic stem cell transplant recipients: Current status, known challenges, and future strategies. Biol Blood Marrow Transplant 2003;9:543-558
5. Steininger C, Puchhammer-Stockl E, Popow-Kraupp T: Cytomegalovirus disease in the era of highly active antiretroviral therapy (HAART). J Clin Virol 2006;37:1-9
6. Kalil AC, Florescu DF: Prevalence and mortality associated with cytomegalovirus infection in nonimmunosuppressed patients in the intensive care unit. Crit Care Med 2009;37:2350-2358
7. Cook CH, Trgovcich J, Zimmerman PD, et al: Lipopolysaccharide, tumor necrosis factor alpha, or interleukin-1beta triggers reactivation of latent cytomegalovirus in immuno-competent mice. J Virol 2006;80:9151-9158
8. Kutza AS, Muhl E, Hackstein H, et al: High incidence of active cytomegalovirus infection among septic patients. Clin Infect Dis 1998;26:1076-1082 (Pubitemid 128751524)
9. Cook CH, Zhang Y, McGuinness BJ, et al: Intra-abdominal bacterial infection reactivates latent pulmonary cytomegalovirus in immunocompetent mice. J Infect Dis 2002;185:1395-1400
10. Docke WD, Prosch S, Fietze E, et al: Cyto-megalovirus reactivation and tumour necrosis factor. Lancet 1994;343:268-269
11. Prosch S, Wendt CE, Reinke P, et al: A novel link between stress and human cytomegalovi-rus (HCMV) infection: Sympathetic hyperactiv-ity stimulates HCMV activation. Virology 2000;272:357-365
12. Higgins TL, Steingrub JS, Tereso GJ, et al: Drotrecogin alfa (activated) in sepsis: Initial experience with patient selection, cost, and clinical outcomes. J Intensive Care Med 2005;20:339-345
13. Bernard GR, Vincent JL, Laterre PF, et al: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709
14. Bernard GR, Ely EW, Wright TJ, et al: Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis. Crit Care Med 2001;29:2051-2059